- Home
- RPRX vs TECK Comparison
RPRX vs TECK Comparison
Compare RPRX & TECK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- TECK
- Stock Information
- Founded
- RPRX 1996
- TECK 1913
- Country
- RPRX United States
- TECK Canada
- Employees
- RPRX N/A
- TECK N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- TECK
- Sector
- RPRX Health Care
- TECK
- Exchange
- RPRX Nasdaq
- TECK Nasdaq
- Market Cap
- RPRX 16.2B
- TECK 20.7B
- IPO Year
- RPRX 2020
- TECK N/A
- Fundamental
- Price
- RPRX $39.29
- TECK $38.68
- Analyst Decision
- RPRX Strong Buy
- TECK Buy
- Analyst Count
- RPRX 3
- TECK 7
- Target Price
- RPRX $46.00
- TECK $54.00
- AVG Volume (30 Days)
- RPRX 3.8M
- TECK 3.2M
- Earning Date
- RPRX 11-05-2025
- TECK 10-22-2025
- Dividend Yield
- RPRX 2.25%
- TECK 0.88%
- EPS Growth
- RPRX N/A
- TECK 166.96
- EPS
- RPRX 1.75
- TECK 1.80
- Revenue
- RPRX $2,349,844,000.00
- TECK $7,526,796,802.00
- Revenue This Year
- RPRX $36.16
- TECK $16.97
- Revenue Next Year
- RPRX $2.04
- TECK $5.95
- P/E Ratio
- RPRX $22.36
- TECK $22.41
- Revenue Growth
- RPRX 3.70
- TECK 29.08
- 52 Week Low
- RPRX $24.05
- TECK $28.32
- 52 Week High
- RPRX $41.24
- TECK $48.47
- Technical
- Relative Strength Index (RSI)
- RPRX 59.22
- TECK 36.85
- Support Level
- RPRX $38.82
- TECK $40.67
- Resistance Level
- RPRX $40.01
- TECK $43.90
- Average True Range (ATR)
- RPRX 1.18
- TECK 1.14
- MACD
- RPRX 0.04
- TECK -0.43
- Stochastic Oscillator
- RPRX 63.07
- TECK 3.20
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About TECK Teck Resources Ltd
Teck is a base metals miner with copper and zinc operations in Canada, the United States, Chile, and Peru. After selling its metallurgical coal business, copper is now its major commodity by EBITDA contribution, followed by zinc. Teck is a top-three zinc miner. Its major new copper mine in Chile at the majority-owned Quebrada Blanca 2, in partnership with Sumitomo, will drive an increase in Teck's attributable copper production by roughly 75%. Along with a number of additional copper growth options, Teck's strategy is to rebalance its portfolio to low-carbon metals such as copper. It sold its oil sands business in early 2023 and its coal business in mid-2024. In September 2025, it agreed to merge with Anglo American.